Navigation Links
Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical
Date:11/30/2009

SHENZHEN, China, Nov. 30 /PRNewswire-FirstCall/ - Hard to Treat Diseases' (HTDS; http://www.htdsmedical.com/) operating subsidiary Mellow Hope finalized contract details with one of the largest manufacturer of intravenous medication in India. This contract promises additional increase in revenues for Hard to Treat Diseases in the following quarters.

The contract between HTDS and the Indian company secures the supply of raw pharmaceutical material to the Indian pharmaceutical company in the range of about 1 million USD. Mellow Hope will be ready to release the shipments shortly. This contract is bound to strengthen Mellow Hope's sales and further increase the value of HTDS.

HTDS' CEO Terry Yuan said, "With our earlier, 4 million USD deal with Indian Hetero Ltd. and our H1N1 vaccine deal with Chile, this is another great news for HTDS. Our business has truly grown in past few months and the investors must appreciate our achievements. With the world growing smaller and smaller, the vaccination market and industry are bound to grow bigger. That's the global trend, and HTDS is definitely a part of it."

Hard to Treat Diseases (HTDS) is also a parent company with operations in Serbia based Slavica Biochem www.slavicabiochem.com. This company focuses on the enhancement and modification of existing and approved medications as well as on cancer research. The MindUp cancer research http://www.mindupbioresearch.com has been delivering groundbreaking results on the international level. The company expects to make some significant news announcement with a separate unrelated pharmaceutical company on this shortly.

To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy however important to the reader and followers of the company please sign up today free at www.minamargroup.com/updates

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters,www.minamargroup.com

SOURCE Hard to Treat Diseases


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Parent training key to improved treatment of behavior problems in children with autism
2. Tailor-made HIV/AIDS treatment closer to reality
3. Natural Soy Component May Help Treat Colon Cancer
4. Cetuximab Helps Treat Colorectal Cancer
5. One Step Closer to New Diabetes Treatment
6. Novel Technology in Treating Chronic Sinus Infections Available at Baptist
7. Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain
8. Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger
9. Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment
10. Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery
11. Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In search of the K. ... theme event of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites ... is sponsored and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), ...
(Date:5/27/2016)... Columbia, SC (PRWEB) , ... May 27, 2016 , ... ... launched a line of classic American timber frame barn kits, which can be found ... are inspired by historic American barn plans, and they highlight the craftsmanship of ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... Texas (PRWEB) , ... May 27, 2016 , ... ... satisfying Army body fat composition regulations. This is the first time that Coolsculpting ... normally screened at least every six months to ensure they meet the prescribed body-fat ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team ... and food industries. Aside from its GMP accreditation, Validation Center is also a ... certified products, services and staff. , Validation Center is ISO17025 accredited and only ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
(Date:5/25/2016)... PUNE, India , May 25, 2016 /PRNewswire/ ... Pipeline Review, H1 2016"market research report that provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:5/24/2016)...   , Study met ... bowel cleansing and superiority in , ... of the ascending colon   ... Norgine B.V. today announced new positive data from the phase ... preparation) versus standard 2 litre PEG with ascorbate. The study met ...
Breaking Medicine Technology: